comparemela.com

Latest Breaking News On - Jeremym levin - Page 2 : comparemela.com

Ovid Therapeutics (NASDAQ:OVID) Earns Buy Rating from Analysts at B Riley

Ovid Therapeutics (NASDAQ:OVID) Earns Buy Rating from Analysts at B Riley
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

HC Wainwright Initiates Coverage on Ovid Therapeutics (NASDAQ:OVID)

HC Wainwright began coverage on shares of Ovid Therapeutics (NASDAQ:OVID – Free Report) in a research note issued to investors on Monday, MarketBeat reports. The firm issued a buy rating and a $9.00 price target on the stock. HC Wainwright also issued estimates for Ovid Therapeutics’ Q1 2024 earnings at ($0.22) EPS, Q2 2024 earnings […]

FFT Wealth Management LLC Invests $1 27 Million in Ovid Therapeutics Inc (NASDAQ:OVID)

FFT Wealth Management LLC acquired a new position in Ovid Therapeutics Inc. (NASDAQ:OVID – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 395,774 shares of the company’s stock, valued at approximately $1,274,000. FFT Wealth Management LLC owned approximately 0.56% of Ovid Therapeutics as of its […]

Ovid Therapeutics (NASDAQ:OVID) Research Coverage Started at HC Wainwright

Ovid Therapeutics (NASDAQ:OVID) Research Coverage Started at HC Wainwright
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Ovid Therapeutics (NASDAQ:OVID) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Ovid Therapeutics (NASDAQ:OVID – Free Report) in a research note issued to investors on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $9.00 price objective on the stock. HC Wainwright also issued estimates for Ovid Therapeutics’ Q1 2024 earnings at ($0.22) EPS, Q2 2024 […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.